Prognostic Significance of Pathologic Nodal Positivity in Non-metastatic Patients with Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy

Overview

Journal Sci Rep

Specialty Science

Date 2021 Feb 5

PMID 33542395

Citations 1

Authors

Sung Han Kim

Boram Park

Eu Chang Hwang

Sung-Hoo Hong

Chang Wook Jeong

Cheol Kwak

Seok Soo Byun

Jinsoo Chung

Affiliations

Soon will be listed here.

Abstract

This retrospective, five-multicenter study was aimed to evaluate the prognostic impact of pathologic nodal positivity on recurrence-free (RFS), metastasis-free (MFS), overall (OS), and cancer-specific (CSS) survivals in patients with non-metastatic renal cell carcinoma (nmRCC) who underwent either radical or partial nephrectomy with/without LN dissection. A total of 4236 nmRCC patients was enrolled between 2000 and 2012, and followed up through the end of 2017. Survival measures were compared between 52 (1.2%) stage pT1-4N1 (LN+) patients and 4184 (98.8%) stage pT1-4N0 (LN-) patients using Kaplan-Meier analysis with the log-rank test and Cox regression analysis to determine the prognostic risk factors for each survival measure. During the median 43.8-month follow-up, 410 (9.7%) recurrences, 141 (3.3%) metastases, and 351 (8.3%) deaths, including 212 (5.0%) cancer-specific deaths, were reported. The risk factor analyses showed that predictive factors for RFS, CSS, and OS were similar, whereas those of MFS were not. After adjusting for significant clinical factors affecting survival outcomes considering the hazard ratios (HR) of each group, the LN+ group, even those with low pT stage, had similar to or worse survival outcomes than the pT3N0 (LN-) group in multivariable analysis and had significantly more relationship with RFS than MFS. All survival measures were significantly worse in pT1-2N1 patients (MFS/RFS/OS/CSS; HR 4.12/HR 3.19/HR 4.41/HR 7.22) than in pT3-4N0 patients (HR 3.08/HR 2.92/HR 2.09/HR 3.73). Therefore, LN+ had an impact on survival outcomes worse than pT3-4N0 and significantly affected local recurrence rather than distant metastasis compared to LN- in nmRCC after radical or partial nephrectomy.

Citing Articles

Non-coding transcriptome profiles in clear-cell renal cell carcinoma.

Tesarova T, Fiala O, Hora M, Vaclavikova R Nat Rev Urol. 2024; 22(3):151-174.

PMID: 39242964 DOI: 10.1038/s41585-024-00926-3.

References

Ljungberg B, Alamdari F, Rasmuson T, Roos G . Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int. 1999; 84(4):405-11. DOI: 10.1046/j.1464-410x.1999.00202.x. View

Lee S, Sung H, Jeon H, Jeong B, Jeon S, Lee H . Size and Volumetric Growth Kinetics of Renal Masses in Patients With Renal Cell Carcinoma. Urology. 2016; 90:119-24. DOI: 10.1016/j.urology.2015.10.051. View

Paparel P, Bigot P, Matillon X, Bensalah K, Salomon L, Baumert H . Local recurrence after radical nephrectomy for kidney cancer: management and prediction of outcomes. a multi-institutional study. J Surg Oncol. 2013; 109(2):126-31. DOI: 10.1002/jso.23473. View

Moschini M, Delloglio P, Larcher A, Capitanio U . Lymph node dissection for renal cell carcinoma: what are we missing?. Curr Opin Urol. 2016; 26(5):424-31. DOI: 10.1097/MOU.0000000000000312. View

Martinez Chanza N, Tripathi A, Harshman L . Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?. Curr Treat Options Oncol. 2019; 20(5):44. DOI: 10.1007/s11864-019-0639-0. View

Terrone C, Cracco C, Porpiglia F, Bollito E, Scoffone C, Poggio M . Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol. 2006; 49(2):324-31. DOI: 10.1016/j.eururo.2005.11.014. View

Herrlinger A, Schrott K, Schott G, Sigel A . What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma. J Urol. 1991; 146(5):1224-7. DOI: 10.1016/s0022-5347(17)38052-7. View

Moron F, Szklaruk J . Learning the nodal stations in the abdomen. Br J Radiol. 2007; 80(958):841-8. DOI: 10.1259/bjr/64292252. View

Babaian K, Kim D, Kenney P, Wood Jr C, Wong J, Sanchez C . Preoperative predictors of pathological lymph node metastasis in patients with renal cell carcinoma undergoing retroperitoneal lymph node dissection. J Urol. 2014; 193(4):1101-7. DOI: 10.1016/j.juro.2014.10.096. View

10.

Zareba P, Russo P . The prognostic significance of nodal disease burden in patients with lymph node metastases from renal cell carcinoma. Urol Oncol. 2019; 37(5):302.e1-302.e6. PMC: 7478336. DOI: 10.1016/j.urolonc.2019.02.006. View

11.

Perrino C, Cramer H, Chen S, Idrees M, Wu H . World Health Organization (WHO)/International Society of Urological Pathology (ISUP) grading in fine-needle aspiration biopsies of renal masses. Diagn Cytopathol. 2018; 46(11):895-900. DOI: 10.1002/dc.23979. View

12.

Crispen P, Breau R, Allmer C, Lohse C, Cheville J, Leibovich B . Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol. 2010; 59(1):18-23. DOI: 10.1016/j.eururo.2010.08.042. View

13.

Byun S, Hong S, Lee S, Kook H, Lee E, Kim H . The establishment of KORCC (KOrean Renal Cell Carcinoma) database. Investig Clin Urol. 2016; 57(1):50-7. PMC: 4778757. DOI: 10.4111/icu.2016.57.1.50. View

14.

Sharma T, Tajzler C, Kapoor A . Is there a role for adjuvant therapy after surgery in "high risk for recurrence" kidney cancer? An update on current concepts. Curr Oncol. 2018; 25(5):e444-e453. PMC: 6209555. DOI: 10.3747/co.25.3865. View

15.

Frees S, Kamal M, Nestler S, Levien P, Bidnur S, Brenner W . Risk-adjusted proposal for >60 months follow up after surgical treatment of organ-confined renal cell carcinoma according to life expectancy. Int J Urol. 2018; 26(3):385-390. DOI: 10.1111/iju.13882. View

16.

Berquist S, Yim K, Ryan S, Patel S, Eldefrawy A, Cotta B . Systemic therapy in the management of localized and locally advanced renal cell carcinoma: Current state and future perspectives. Int J Urol. 2019; 26(5):532-542. DOI: 10.1111/iju.13943. View

17.

Zhang B, Thompson R, Lohse C, Leibovich B, Boorjian S, Cheville J . A novel prognostic model for patients with sarcomatoid renal cell carcinoma. BJU Int. 2014; 115(3):405-11. DOI: 10.1111/bju.12781. View

18.

Nini A, Larcher A, Cazzaniga W, Delloglio P, Cianflone F, Muttin F . The side and the location of the primary tumor does not affect the probability of lymph node invasion in patients with renal cell carcinoma. World J Urol. 2018; 37(8):1623-1629. DOI: 10.1007/s00345-018-2573-3. View

19.

Lee H, Kim Y, Hwang E, Kang S, Hong S, Chung J . Preoperative cholesterol level as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with cyto-reductive nephrectomy. BMC Cancer. 2017; 17(1):364. PMC: 5445323. DOI: 10.1186/s12885-017-3322-5. View

20.

Dimashkieh H, Lohse C, Blute M, Kwon E, Leibovich B, Cheville J . Extranodal extension in regional lymph nodes is associated with outcome in patients with renal cell carcinoma. J Urol. 2006; 176(5):1978-82. DOI: 10.1016/j.juro.2006.07.026. View